Medtronic unit's valve replacement device gets approval in Europe

12/9/2010 | MedCityNews.com

Medtronic's CoreValve division has secured CE Mark approval for its a valve-replacement system that can treat severe aortic stenosis without requiring patients to undergo open-heart surgery. Medtronic paid $700 million to purchase CoreValve in 2009.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC